Careers  |  Sign In  |  Register  |   Twitter

Latest in Oncology

Reuters reports that Adriad Pharmaceuticals Inc. has discontinued a late-stage trial of its leukemia drug, Iclusig. The drug, which was approved by the FDA for two forms of blood cancer, has now been shown to cause blood clots. Though the drug's shares have now plunged to a three-year low of $2.62, it still...

Reuters Health • The Doctor's Channel Daily Newscast

Endosonography More Cost-Effective Than Surgical Staging in Lung Cancer

NEW YORK (Reuters Health) – A European study indicates that starting with endosonography for assessing mediastinal lymph node status in potentially resectable lung cancer is more cost-effective than immediate surgical staging – at least in the UK, The Netherlands and Belgium where the study was...

Reuters Health • The Doctor's Channel Daily Newscast

Pomalidomide-Dexamethasone Beneficial in Refractory Multiple Myeloma

NEW YORK (Reuters Health) – The combination of pomalidomide and low-dose dexamethasone improves survival in patients with advanced multiple myeloma more than does treatment with high-dose dexamethasone alone, a multinational study has shown. “Pomalidomide plus low-dose dexamethasone, an oral regimen,...